<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92581">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02134054</url>
  </required_header>
  <id_info>
    <org_study_id>SUSI-CS_1</org_study_id>
    <nct_id>NCT02134054</nct_id>
  </id_info>
  <brief_title>Stavanger IBD Study - Cross Sectional</brief_title>
  <acronym>SUSI-CS</acronym>
  <official_title>Stavanger University Hospital IBD Study - a Cross Sectional Longitudinal Study on Patients Treated With Biologics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital Rikshospitalet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital Radiumhospitalet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <authority>Norway: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this cross sectional and longitudinal study, patients with inflammatory bowel disease on
      biological treatment with infliximab or adalimumab will be included.

      After inclusion, the dosage of their existing biological therapy will be adjusted following
      regular trough-level and antibody-level monitoring, according to a treatment algorithm.

      Disease activity markers, fatigue and QoL will be assessed during the study. The hypothesis
      is that therapeutic drug monitoring may improve clinical disease outcome after one year of
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Harvey Bradshaw Index &lt;5 Partial Mayo score &lt;=2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scoring</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Harvey Bradshaw Index, Partial Mayo Score. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>C reactive protein, Fecal Calprotectin. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue scoring</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by Fatigue severity scale and Visual analogue scale. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Healthcare resource utilization</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Registration of
Outpatient visits
Hospital admissions (days)
Sick leave (days)
Visits at general practitioner due to IBD activity
Endoscopy due to IBD activity</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Biologic</arm_group_label>
    <description>Patients on treatment with biologics (infliximab or adalimumab)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Standard blood sampling Serum sampling - trough/antibodies of biological agent
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with inflammatory bowel disease established (minimum 3 doses) on treatment with
        infliximab or adalimumab
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with inflammatory bowel disease on treatment with infliximab or
             adalimumab of any duration (at least 3 doses)

        Exclusion Criteria:

          -  Inability to consent

          -  Inability to adhere to treatment protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tore B Grimstad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stavanger University Hospital, Department of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tore B Grimstad, MD, PhD</last_name>
    <phone>+47 90921650</phone>
    <email>tore.bjorn.grimstad@sus.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars N Karlsen, MD</last_name>
    <phone>+4705151</phone>
    <email>lars.normann.karlsen@sus.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lars N Karlsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Biological treatment</keyword>
  <keyword>IBD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
